Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 4.49

From 52W high−26.38%

Volume5.84M

Market capCNY 6.36B

P/E (TTM)−60.9x

P/S (TTM)2.1x

Div yield—

Key dataSep 18, 2026

Open

CNY 4.49

From 52W high

−26.38%

Volume

5.84M

Market cap

CNY 6.36B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

34.9x

P/E (TTM)

−60.9x

RSI (14)

44.6

MomentumView details →

1D Return

+0.66%

YTD Return

+3.45%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−60.9x

EV/EBITDA

34.9x

EV/Sales

2.4x

P/S (TTM)

2.1x

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

46.10%

Net Margin

−3.42%

EBITDA Margin

6.90%

ROE (TTM)

−3.15%

ROA (TTM)

−1.69%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

−9.87%

EPS YoY

—

FCF YoY

+111.85%

Revenue CAGR 3Y

−4.86%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.66%

YTD Return

+3.45%

1Y Return

−20.35%

RSI (14)

44.6

vs 50D SMA

−1.42%

vs 200D SMA

−4.92%

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

0.95x

Quick Ratio

0.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

+175.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.93B

Net Income (TTM)

−100.35M

Op. CF (TTM)

595.95M

Latest newsMore news →

ST Bailing completed the cancellation of 12.0969 million repurchased shares, reducing its total share capital by 0.87%, effective September 8, 2026.11d ago

ST Bailing's wholly-owned subsidiary received pre-approval from the Macao SAR Drug Administration (ISAF) to conduct a Phase III clinical trial for its traditional Chinese medicine product Tangningtongluo Tablet, the first such pre-approval for a new TCM drug in Macao.23d ago

Similar companies

华孚时尚002042.SZ 联得装备300545.SZ 金正大002470.SZ 美联新材300586.SZ 海陆重工002255.SZ 凯旺科技301182.SZ Find similar companies →

Latest newsMore news →

ST Bailing completed the cancellation of 12.0969 million repurchased shares, reducing its total share capital by 0.87%, effective September 8, 2026.11d ago ST Bailing's wholly-owned subsidiary received pre-approval from the Macao SAR Drug Administration (ISAF) to conduct a Phase III clinical trial for its traditional Chinese medicine product Tangningtongluo Tablet, the first such pre-approval for a new TCM drug in Macao.23d ago